HAND2 and lung cancer: Furthermore, with regard to DFS, higher HAND2-AS1 expression demonstrated a higher DFS rate in breast cancer, colon cancer, CRC, liposarcoma, lung cancer, melanoma, and non-small cell lung cancer (Fig. 7B).